EXPECTED BEST SELLING PRODUCTS OF 2022
Comirnaty is a messenger RNA (mRNA) based COVID vaccine developed by Pfizer and BioNTech. Based on the median follow-up of 2 months, the efficacy of two doses of Comirnaty is 95%.
Pfizer reported revenues of $36.78 billion in 2021 from Comirnaty.
AbbVie's blockbuster Humira is expected to earn $20.35 billion in 2022. However, 2022 is the last year for Humira to retain the status of the best-selling product, excluding the COVID19 vaccines. Biosimilars are already available in Europe and will enter the US market from March 2023.
Merck's PD-L1 inhibitor, Keytruda, which was approved in 2014 for melanoma, is now approved for more than fifteen different cancers. Merck is pushing aggressively for earlier lines of treatment.
Keytruda acts by blocking the PD-1 pathway. PD-1 pathway is being used by the cancer cells to escape the immune system, thereby helping the immune system to detect and kill the cancer cells.
Spikevax is another COVID19 vaccine from Moderna and is anticipated to generate revenues of $19.5 billion.
Eliquis is developed by BMS and Pfizer and is expected to earn revenues of $11.2 billion. In 2007, Pfizer and BMS agreed to collaborate on the development of Eliquis worldwide.
Eliquis is a factor Xa inhibitor used to reduce stroke in patients with nonvalvular atrial fibrillation, prevent deep vein thrombosis (DVT), and treat DVT and PE.
Revlimid is a drug that treats multiple myeloma (MM), transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS), mantle cell lymphoma, follicular and marginal zone lymphoma.
Revlimid acts by showing immunomodulatory properties (activating and increasing T-cells and NK cells, inhibiting pro-inflammatory cytokines), inducing apoptosis, and reducing the levels of VEGF, TNF-a, and IL-6, thereby stopping angiogenesis.
Janssen's Stelara, a psoriasis drug also approved for several other indications, is anticipated to generate revenues of $10.1 billion.
Stelara acts by blocking IL-12 and IL-23 proteins of immune systems, thereby preventing inflammation.
Biktarvy is indicated for treating HIV-1 infection. It does not cure HIV infection. Biktarvy is combination of bictegravir/emtricitabine/tenofovir alafenamide. It is expected to generate revenues of $9.8 billion.
BMS Opdivo, another PD-L1 inhibitor, is expected to generate revenues of $ 9 billion.
Dupixent is indicated for asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis (CRSwNP).
Dupixent prevents inflammation by inhibiting IL-4Rα, thereby inhibiting IL-4 and IL-13 signaling.
Source of revenue forecast: